Product Name
Plasminogen activator inhibitor 1 (PAI-1) human, recombinant, expressed in E. coli, ≥90% (SDS-PAGE)
recombinant
expressed in E. coli
Quality Segment
assay
≥90% (SDS-PAGE)
form
lyophilized powder
specific activity
≥200,000 units/mg protein
mol wt
~43 kDa
solubility
water: 0.1 mL, clear, colorless
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... SERPINE1(5054)
General description
Plasminogen activator inhibitor 1 (PAI-1) or serine protease inhibitor E1 (SERPINE1) gene is mapped to human chromosome 7q22.1. PAI-1 is produced in hepatocytes, endothelial cells, smooth muscle cells, megakaryocytes, and adipocytes.
Application
Plasminogen activator inhibitor 1 (PAI-1) human has been used:
- as an inhibitor of pro-brain-derived neurotrophic factor (proBDNF) in radioimmunoprecipitation assay (RIPA) in peripheral blood and lymphocytes
- to block plasmin activation in mice infected with C. albicans hyphae
- to test its effect on neurite growth in neurons
Biochem/physiol Actions
Plasminogen Activator Inhibitor 1 (PAI-1) protein belongs to the Serpin superfamily of serine protease inhibitors. It is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and therefore inhibits the fibrinolysis process. PAI is involved in extracellular matrix remodeling and has been implicated in processes like angiogenesis, chemotaxis, ovulation, and embryogenesis. PAI-1 is present in increased levels in various disease states such as a number of cancer forms, obesity and the metabolic syndrome.
Plasminogen activator inhibitor 1 (PAI-1), a member of the Serpin superfamily of serine protease inhibitors, is involved in extracellular matrix remodeling and implicated in processes like angiogenesis, chemotaxis, ovulation, and embryogenesis.
Plasminogen activator inhibitor–1 (PAI -1) participates in mediating cellular senescence. It is upregulated during injury along with other tissue repair transcriptomes. Elevated levels of PAI-1 is regarded as one of the risks associated with myocardial infarction (MI).
Physical form
Supplied as a lyophilized powder from a solution containing 0.5 M sodium chloride, 20 mM sodium acetate, and 50 mg/mL trehalose.
Preparation Note
Reconstitute to 0.25 mg/ml with ultrapure water. The reconstituted product contains 0.25 mgP/mL in 0.5 M sodium chloride, 20 mM sodium acetate, and 50 mg/mL trehalose.
Analysis Note
The product is the active human PAI-1 protein with a molecular weight of 43 kDa.
Other Notes
1 unit irreversibly inhibits (100% inhibition) 1 unit of tissue plasminogen activator (tPA) under physiological conditions (neutral pH and 37 ºC).
Storage Class
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.